Secondary Analyses of Osteoporosis Screening in Older Men
Secondary Analyses of Osteoporosis Screening in Older Men
批准号:
8919200
负责人:
MARGARET L GOURLAY
金额:
$26.91万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2017-04-30
关键词:
AccountingAgeAged, 80 and overBone DensityCause of DeathCessation of lifeClinicalClinical Practice GuidelineCommunitiesDataData AnalysesElderlyExpert OpinionForearm FractureFractureGoalsHealthHip FracturesHip region structureIncidenceMethodsObservational StudyOsteoporosisOutcomePharmaceutical PreparationsPrevalencePreventionPrevention GuidelinesRandomized Controlled TrialsRelative (related person)RiskRisk AssessmentRisk FactorsShoulder FracturesSpinal FracturesStratificationTestingTimeVertebral columnWomanage groupagedbasebisphosphonateclinical riskcohortcomparativecostdiagnostic accuracyevidence baseexperiencehigh riskhigh risk menhip bonehuman old age (65+)interestmenolder menolder womenosteoporosis with pathological fracturepreventscreeningtool
中文摘要
描述(由申请人提供):在美国,男性占骨折的29%,占骨折相关费用的25%。尽管与女性相比,男性骨折发生率较低,但男性在髋部骨折后1年内死亡的可能性更大,因此受到特别关注。
英文摘要
DESCRIPTION (provided by applicant): Men account for 29% of fractures and 25% of fracture-related costs in the US. Although fewer fractures occur in men compared to women, men are of special interest because they are more likely to die within 1 year after a hip fracture.
Bone mineral density (BMD) testing to identify and treat osteoporosis (very low BMD) has been proposed as a method to prevent disabling fractures in older men, largely because this is an accepted screening strategy in women aged 65 years and older. However, the efficacy of BMD screening in men is uncertain. Because an RCT of osteoporosis screening is not considered feasible, observational studies are needed to test how BMD screening should be used for identification of older men at high risk of fracture, and to assess whether death from other (non-fracture-related) causes overwhelms the risk of incident hip or clinical vertebral fracture in the "oldest old" of men. Risk factor assessment should also be studied because clinical practice guidelines recommend risk assessment to guide the selection of men for BMD screening. Our long-term goal is to identify a high-risk group of older men that should have routine BMD screening and risk factor assessment to select candidates for medications to reduce major fractures. We hypothesize that in men aged 65 and older, the relative incidence of first hip or clinical vertebral fracture vs. incidence of other-cause death will peak within an optimal age range when BMD screening could be considered, with subsequent decreasing benefit from BMD screening with increasing age. We further hypothesize that clinical risk factors will predict incident hip or clinical vertebral fracture as accurately as BMD in older men. Our planned analyses of data from the Osteoporotic Fractures in Men Study (MrOS) will inform a selective BMD screening strategy for a high-risk group of older men, accommodating men's clinical risk factors for fracture and increasingly higher rate of other-cause death with advancing age. Specific aims of this project: 1) Compare the time to first hip or clinical vertebral fracture vs. ime to other-cause death according to age group in older men; 2) Compare the time to first hip or clinical vertebral fracture in older men with lower vs. higher baseline BMD T-scores; 3) Estimate the accuracy of fracture risk assessment scores without and with BMD to predict hip or major osteoporotic fracture in older men. Impact: Successful completion of these aims will demonstrate that BMD screening in a high-risk group of older men will predict significant numbers of major fracture cases, and will test whether risk factor assessment is a strong adjunct to BMD screening in men. These findings would provide a stronger evidence base for men's fracture prevention guidelines than those currently based on expert opinion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Secondary Analyses of Osteoporosis Screening in Older Men
-
批准号:8761398
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2014
-
负责人:MARGARET L GOURLAY
-
依托单位:
Secondary Analyses of Osteoporosis Screening in Older Men
-
批准号:9053419
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2014
-
负责人:MARGARET L GOURLAY
-
依托单位:
FSH as a biomarker of bone strength in younger postmenopausal women
-
批准号:7686746
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2008
-
负责人:MARGARET L GOURLAY
-
依托单位:
SELECTIVE SCREENING FOR OSTEOPOROSIS IN YOUNGER POSTMENOPAUSAL WOMEN
-
批准号:7716818
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2008
-
负责人:MARGARET L GOURLAY
-
依托单位:
FSH as a biomarker of bone strength in younger postmenopausal women
-
批准号:7876896
-
项目类别:
-
资助金额:$7.33万
-
财政年份:2008
-
负责人:MARGARET L GOURLAY
-
依托单位:
FSH as a biomarker of bone strength in younger postmenopausal women
-
批准号:7531441
-
项目类别:
-
资助金额:$7.38万
-
财政年份:2008
-
负责人:MARGARET L GOURLAY
-
依托单位:
Selective screening for osteoporosis in younger postmenopausal women
-
批准号:7212753
-
项目类别:
-
资助金额:$13.24万
-
财政年份:2007
-
负责人:MARGARET L GOURLAY
-
依托单位:
Selective screening for osteoporosis in younger postmenopausal women
-
批准号:8101901
-
项目类别:
-
资助金额:$13.24万
-
财政年份:2007
-
负责人:MARGARET L GOURLAY
-
依托单位:
Selective screening for osteoporosis in younger postmenopausal women
-
批准号:7467908
-
项目类别:
-
资助金额:$13.24万
-
财政年份:2007
-
负责人:MARGARET L GOURLAY
-
依托单位:
Selective screening for osteoporosis in younger postmenopausal women
-
批准号:7641010
-
项目类别:
-
资助金额:$13.24万
-
财政年份:2007
-
负责人:MARGARET L GOURLAY
-
依托单位:
MEASUREMENT OF THREE BIOCHEMICAL MARKERS OF BONE METABOLISM
-
批准号:7625609
-
项目类别:
-
资助金额:$0.58万
-
财政年份:2006
-
负责人:MARGARET L GOURLAY
-
依托单位:
MEASUREMENT OF THREE BIOCHEMICAL MARKERS OF BONE METABOLISM
-
批准号:7377562
-
项目类别:
-
资助金额:$0.64万
-
财政年份:2005
-
负责人:MARGARET L GOURLAY
-
依托单位:
FACTORS ASSOCIATED WITH LOW BONE MINERAL DENSITY IN WOMEN 20-49
-
批准号:7200289
-
项目类别:
-
资助金额:$1.29万
-
财政年份:2004
-
负责人:MARGARET L GOURLAY
-
依托单位:
Factors Associated with Low Bone Mineral Density in Women 20-49
-
批准号:6980724
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2003
-
负责人:MARGARET L GOURLAY
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: